Pemigatinib

Fibroblast growth factor receptor alterations define the population treated with pemigatinib, a targeted small-molecule therapy. Where an FGFR gene fusion or rearrangement produces a constitutively active receptor, the resulting signal drives proliferation independently of normal growth-factor control; inhibiting the abnormal protein removes that drive. Treatment therefore depends on molecular characterisation of the tumour rather than on its site of origin alone, the pattern common to genomically selected therapies. Selection by genotype also narrows the eligible population sharply compared with histology-defined indications. The compound is a small molecule with the formula C24H27F2N5O4 and a molecular weight of approximately 487.5 g/mol, and it is an approved agent whose clinical development has reached the final phase.

SMILES

CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21

InChI

InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)